• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Resolution of long standing hypergammaglobulinemic purpura of Waldenström after initiating treatment for cystic fibrosis with Elexacaftor-Tezacaftor-Ivacaftor.

作者信息

Tantuco Kimberly, Beecker Jennifer, Chin Melanie

机构信息

Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Division of Dermatology, the Ottawa Hospital, Ottawa, Ontario, Canada.

出版信息

JAAD Case Rep. 2023 Oct 15;44:68-70. doi: 10.1016/j.jdcr.2023.09.037. eCollection 2024 Feb.

DOI:10.1016/j.jdcr.2023.09.037
PMID:38283045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10820255/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a00/10820255/521440b07ec0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a00/10820255/82ee2d64603f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a00/10820255/6a3b706a61b3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a00/10820255/521440b07ec0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a00/10820255/82ee2d64603f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a00/10820255/6a3b706a61b3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a00/10820255/521440b07ec0/gr3.jpg

相似文献

1
Resolution of long standing hypergammaglobulinemic purpura of Waldenström after initiating treatment for cystic fibrosis with Elexacaftor-Tezacaftor-Ivacaftor.在用依列卡福-替扎卡福-依伐卡福开始治疗囊性纤维化后，瓦尔登斯特伦长期存在的高球蛋白血症性紫癜得到缓解。
JAAD Case Rep. 2023 Oct 15;44:68-70. doi: 10.1016/j.jdcr.2023.09.037. eCollection 2024 Feb.
2
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
3
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
4
Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.依伐卡托与泰他卡托和艾克巴司他联合制剂治疗囊性纤维化慢性鼻-鼻窦炎的疗效。
Am J Otolaryngol. 2024 May-Jun;45(3):104236. doi: 10.1016/j.amjoto.2024.104236. Epub 2024 Feb 24.
5
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.无 F508del CFTR 变异的囊性纤维化患者使用依伐卡托、泰它西普和埃拉卡托的法国扩大同情用药计划：一项真实世界研究。
Lancet Respir Med. 2024 Nov;12(11):888-900. doi: 10.1016/S2213-2600(24)00208-X. Epub 2024 Aug 13.
6
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
7
Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.高效CFTR调节剂疗法对囊性纤维化患儿的实际影响。
Front Pharmacol. 2023 May 9;14:1176815. doi: 10.3389/fphar.2023.1176815. eCollection 2023.
8
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对具有 II 类 CFTR 基因突变（最常见的是 F508del）的囊性纤维化患者的校正治疗（含或不含增效剂）。
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.
9
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
10
Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.基于生理的药代动力学引导用于 COVID-19 治疗中接受 Elexacaftor-Tezacaftor-Ivacaftor 联合奈玛特韦-利托那韦治疗的囊性纤维化患者。
Clin Pharmacol Ther. 2022 Jun;111(6):1324-1333. doi: 10.1002/cpt.2585. Epub 2022 Apr 6.

本文引用的文献

1
A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy.三联卡法托（Trikafta）综述：三联囊性纤维化跨膜传导调节因子（CFTR）调节剂疗法
Cureus. 2021 Jul 3;13(7):e16144. doi: 10.7759/cureus.16144. eCollection 2021 Jul.
2
Hypergammaglobulinemic purpura of Waldenström in children.
Pediatr Dermatol. 2020 May;37(3):467-475. doi: 10.1111/pde.14120. Epub 2020 Feb 27.
3
Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.囊性纤维化：将分子机制转化为有效的治疗方法。
Ann Am Thorac Soc. 2018 Aug;15(8):897-902. doi: 10.1513/AnnalsATS.201802-075FR.
4
JAAD grand rounds. Persistent and progressive purpura in a patient with an elevated rheumatoid factor and polyclonal gammopathy (hypergammaglobulinemic purpura of Waldenström).
J Am Acad Dermatol. 2015 Feb;72(2):374-6. doi: 10.1016/j.jaad.2013.02.020.
5
Cystic fibrosis.囊性纤维化
Lancet. 2003 Feb 22;361(9358):681-9. doi: 10.1016/S0140-6736(03)12567-6.
6
Hypergammaglobulinemic purpura of Waldenström: report of 3 cases with a short review.
Clin Exp Rheumatol. 2000 Jul-Aug;18(4):518-22.
7
Hypergammaglobulinemic purpura of Waldenstrom associated with systemic lupus erythematosus: report of a case and review of the literature.
Lupus. 1995 Feb;4(1):19-22. doi: 10.1177/096120339500400105.
8
Purpuric rashes in cystic fibrosis.
Am J Dis Child. 1989 Sep;143(9):1030-2. doi: 10.1001/archpedi.1989.02150210056018.
9
Cutaneous manifestations of cystic fibrosis: possible role of cryoglobulins.
Br J Dermatol. 1989 Nov;121(5):655-8. doi: 10.1111/j.1365-2133.1989.tb08199.x.
10
Hypergammaglobulinemic purpura of Waldenström.
J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):669-76. doi: 10.1016/0190-9622(90)70271-i.